Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Effect of Ormeloxifene for Management of Dysfunctional Uterine Bleeding
| Hari Om Singh1*, Amita Singh2, TN Dhole1 and Sumitra Nain3 | |
| 1Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow-226014, India | |
| 2Department of Obstetrics and Gynecology, CHC, Sarai Akil, Allahabad-212206, India | |
| 3Department of Pharmacy, Banasthali University, Banasthali, Rajasthan-304022, India | |
| Corresponding Author : | Hari Om Singh Department of Molecular Virology National AIDS Research Institute (ICMR) Department of Health Research (MOH and FW) GOI 73 ‘G’ Block, MIDC, Bhosari, Pune -411026, India Tel: +91-020-27331200 (1244-O) Fax: +91-020-272121071 E-mail: hsingh@nariindia.org, hariomsgpgims@gmail.com |
| Received July 06, 2015; Accepted August 01, 2015; Published August 08, 2015 | |
| Citation: Singh HO, Singh A, Dhole TN, Nain S (2015) Effect of Ormeloxifene for Management of Dysfunctional Uterine Bleeding. Biochem Physiol 4:174. doi: 10.4172/2168-9652.1000174 | |
| Copyright: © 2015 Singh HO, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | |
| Related article at Pubmed, Scholar Google | |
Abstract
Menorrhagia is an abnormal vaginal bleeding. Ormeloxifene is anti proliferative drugs which reduce production of various endometrial derived local factors and corrects menorrhagia with decrease menstrual blood loss (MBL) and clots. Therefore, we aimed to determine the effect of Ormeloxifene in women with dysfunctional uterine bleeding. We enrolled a total of 172 patients, aged 25 to 45 year, attended outpatient of gynecology department with complaints of heavy menstrual blood flow. Ormeloxifene was administered orally twice a week for first 12 weeks and then once in a week for next 12 weeks. MBL was measured using pictorial blood loss assessment chart (PBAC), blood hemoglobin. The median difference between pretreatment and post-treatment PBAC score was found to be significant. Similarly, It was also same with the difference in mean hemoglobin between pretreatment and post-treatment levels. The frequency distribution of clots during post treatment was significant as compared to pretreatment. Ormeloxifene is a cost effective effect therapy.
